Codexis, Inc. is an industrial biotechnology company that specializes in engineers enzymes for pharmaceutical and chemical production through biocatalysis. Codexis’ technologies enable scale-up and implementation of biocatalytic solutions to optimize process development, from research to manufacturing. There are currently over 50 pharmaceutical firms using Codexis’ technology, products and services in their manufacturing process development.
Codexis creates its products by applying its CodeEvolver® directed evolution technology platform, which introduces genetic mutations into microorganisms.
Codexis, Inc. began operations as an independent company in 2002, and became a publicly traded company in 2009. They are located in Redwood City, CA USA
Closing share price